Cited by 356Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record, with a small difference in title or year; 9 of the 9 references it cites were found in a registry or an index.

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Open access

Ray, Kausik K., Cannon, Christopher P., McCabe, Carolyn H., Cairns, Richard, Tonkin, Andrew M., Sacks, Frank M., Jackson, Graham, Braunwald, Eugene·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2005.03.077

Open this paper in CoChat — free account Open PDF

Abstract

Objectives Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients.Background The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients versus standard therapy. The relative contributions of early or late effects to the overall clinical efficacy of intensive therapy are presently unclear.Methods A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy (pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for recurrent ACS was determined in each group at 30 days. The composite triple and primary end points were assessed in stable patients from six months to the end of study, after censoring for clinical events before six months.Results The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR] = 0.72; 95% confidence interval [CI], 0.52 to 0.99; p = 0.046). In stable patients, atorvastatin 80 mg was associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group (HR = 0.72; 95% CI, 0.58 to 0.89; p = 0.003).Conclusions Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2005.03.077

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citation
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R. M., Frey, M. J., Lakkis, N. M., Neumann, F., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,093
Self-citation
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation
Ray, K., & Cannon, C. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-004-0205-9 · Cited by 43
Self-citation

Show all 9 references

Research works printed but not linked: 1

1994, Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, Lancet, 344, 1383

Sorted by citations

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,865
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Untitled work
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,435
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citation
American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
Graham, I. M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.024 · Cited by 716
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 702
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment
Insull, W. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.10.013 · Cited by 677
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.038 · Cited by 610
Self-citation
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial
Räber, L., Ueki, Y., Otsuka, T., Losdat, S., Häner, J. D., Lonborg, J., Fahrni, G., Iglesias, J. F., van Geuns, R.-J., Ondracek, A. S., et al. (2022) · JAMA · doi:10.1001/jama.2022.5218 · Cited by 591
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention
Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G., Montinaro, A., & Sciascio, G. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.025 · Cited by 483
Coronary Microembolization
Heusch, G., Kleinbongard, P., Böse, D., Levkau, B., Haude, M., Schulz, R., & Erbel, R. (2009) · Circulation · doi:10.1161/circulationaha.109.888784 · Cited by 418
Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation
Tawakol, A. A., Fayad, Z. A., Mogg, R., Alon, A., Klimas, M. T., Dansky, H. M., Subramanian, S. S., Abdelbaky, A., Rudd, J. H. F., Farkouh, M. E., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.066 · Cited by 420
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rosselló, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 373
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 319
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Koskinas, K. C., Windecker, S., Pedrazzini, G., Mueller, C. E., Cook, S., Matter, C. M., Müller, O., Häner, J. D., Gencer, B., Crljenica, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.010 · Cited by 296
Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277984.31558.c4 · Cited by 299
Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy
Kini, A. S., Baber, U., Kovacic, J. C., Limaye, A. M., Ali, Z. A., Sweeny, J. M., Maehara, A., Mehran, R., Dangas, G., Mintz, G. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.058 · Cited by 283
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation
Tang, J., Lobatto, M. E., Hassing, L., van der Staay, S. E. M., van Rijs, S. M., Calcagno, C., Braza, M. S., Baxter, S., Fay, F., Sánchez-Gaytán, B. L., et al. (2015) · Science Advances · doi:10.1126/sciadv.1400223 · Cited by 228
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Statins as Antithrombotic Drugs
Violi, F., Calvieri, C., Ferro, D., & Pignatelli, P. (2013) · Circulation · doi:10.1161/circulationaha.112.145334 · Cited by 206
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women
Alexopoulos, N. A., Melek, B. H., Arepalli, C. D., Hartlage, G. R., Chen, Z., Kim, S., Stillman, A. E., & Raggi, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.051 · Cited by 185
Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers
Yasue, H., Mizuno, Y., Harada, E., Itoh, T., Nakagawa, H., Nakayama, M., Ogawa, H., Tayama, S., Honda, T., Hokimoto, S., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.049 · Cited by 178
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120479 · Cited by 190
Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem
Hayward, R. A., Hofer, T. P., & Vijan, S. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-7-200610030-00010 · Cited by 163
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial
Ganesan, A., Crum‐Cianflone, N. F., Higgins, J. M., Qin, J., Rehm, C. A., Metcalf, J. A., Brandt, C., Vita, J., Decker, C. F., Sklar, P. A., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq115 · Cited by 156
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Afilalo, J., Majdan, A. A., & Eisenberg, M. J. (2007) · Heart · doi:10.1136/hrt.2006.112508 · Cited by 143
Cardiovascular effects of statins, beyond lipid-lowering properties
Mihos, C. G., Pineda, A. M., & Santana, O. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.009 · Cited by 148
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citation
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel, T. N., Shishehbor, M. H., & Bhatt, D. L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl445 · Cited by 119
Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Mannu, G., Zaman, M., Gupta, A., Rehman, H. U., & Myint, P. K. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076313 · Cited by 121
A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications
Oikonomou, E. K., Leopoulou, M., Theofilis, P., Antonopoulos, A. S., Siasos, G., Latsios, G., Mystakidi, V. C., Antoniades, C. A., & Tousoulis, D. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.027 · Cited by 117
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
Banach, M., Penson, P. E., Vrablı́k, M., Bunc, M., Dyrbuś, K., Fedačko, J., Gaiță, D. I., Gierlotka, M. J., Járai, Z., Magda, S. L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105499 · Cited by 102
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D. H., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 102
Impact of adherence to statins on coronary artery disease in primary prevention
Bouchard, M.-H., Dragomir, A., Blais, L., Bérard, A., Pilon, D., & Perreault, S. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02828.x · Cited by 102
Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy
Hirayama, A., Saito, S., Ueda, Y., Takayama, T., Honye, J., Komatsu, S., Yamaguchi, O., Li, Y., Yajima, J., Nanto, S., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-0755 · Cited by 96
Guía europea de prevención cardiovascular en la práctica clínica: Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Álvarez-Sala, L., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano‐Álvarez, A., et al. (2008) · Revista Española de Salud Pública · doi:10.1590/s1135-57272008000600002 · Cited by 97
The Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Cardiovascular Disease
Mihos, C. G., Salas, M. J., & Santana, O. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181f52a7f · Cited by 96
Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy
Corrao, G., Conti, V., Merlino, L. G., Catapano, A. L., & Mancia, G. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.004 · Cited by 91
Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment
Merwick, Á., Albers, G. W., Arsava, E. M., Ay, H., Calvet, D., Coutts, S. B., Cucchiara, B. L., Demchuk, A. M., Giles, M. F., Mas, J.-L., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001576 · Cited by 89
Cellular and molecular mechanisms of statins: an update on pleiotropic effects
Satoh, M., Takahashi, Y., Tabuchi, T., Minami, Y., Tamada, M., Takahashi, K., Itoh, T., Morino, Y., & Nakamura, M. (2015) · Clinical Science · doi:10.1042/cs20150027 · Cited by 92
Low-Density Lipoprotein Cholesterol Level in Patients With Acute Myocardial Infarction Having Percutaneous Coronary Intervention (the Cholesterol Paradox)
Cho, K. H., Jeong, M. H., Ahn, Y., Kim, Y. J., Chae, S. C., Hong, T. J., Seong, I. W., Chae, J. K., Kim, C. J., Cho, M., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.009 · Cited by 87
Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR
Galve, E., Cordero, A., Cequier, A. R., Ruiz, E., & González‐Juanatey, J. R. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.02.013 · Cited by 82
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
Gibson, C. M., Kastelein, J. J. P., Phillips, A. T., Aylward, P. E., Yee, M. K., Tendera, M., Nicholls, S. J., Pocock, S., Goodman, S. G., Alexander, J. H., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.052 · Cited by 87
Effect of Statin Therapy on Mortality in Patients With Peripheral Arterial Disease and Comparison of Those With Versus Without Associated Chronic Obstructive Pulmonary Disease
van Gestel, Y. R. B. M., Hoeks, S. E., Sin, D. D., Şimşek, C., Welten, G. M. J. M., Schouten, O., Stam, H. J., Mertens, F. W., van Domburg, R. T., & Poldermans, D. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.03.038 · Cited by 83
Rapid Stabilization of Vulnerable Carotid Plaque Within 1 Month of Pitavastatin Treatment in Patients With Acute Coronary Syndrome
Nakamura, T., Obata, J., Kitta, Y., Takano, H., Kobayashi, T., Fujioka, D., Saitō, Y., Kodama, Y., Kawabata, K., Mende, A., et al. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318165dcad · Cited by 78
Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial
Mehta, S. R., Paré, G., Lonn, E., Jolly, S. S., Natarajan, M. K., Pinilla‐Echeverri, N., Schwalm, J.-D., Sheth, T., Sibbald, M., Tsang, M., et al. (2022) · EuroIntervention · doi:10.4244/eij-d-22-00735 · Cited by 79
The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Zhao, S., Yu, B., Peng, D., & Huo, Y. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.003 · Cited by 77
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.016 · Cited by 72
Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall
Kajimoto, K., Miyauchi, K., Kasai, T., Shimada, K., Kojima, Y., Shimada, A., Niinami, H., Amano, A., & Daida, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.028 · Cited by 73
Plaque Stabilization: Can We Turn Theory into Evidence?
Libby, P., & Sasiela, W. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.017 · Cited by 72
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study
Płazak, W., Gryga, K., Dziedzic‐Oleksy, H., Pająk, L. T., Konieczyńska, M., Podolec, P. S., & Musiał, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3402 · Cited by 73
Pleiotropic Effects and Cholesterol-Lowering Therapy
Shaw, S. M., Fildes, J. E., Yonan, N. A., & Williams, S. G. (2008) · Cardiology · doi:10.1159/000137692 · Cited by 70
Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults With Limited Prior Drug Coverage
McWilliams, J. M., Zaslavsky, A. M., & Huskamp, H. A. (2011) · JAMA · doi:10.1001/jama.2011.1026 · Cited by 69
Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial)
LaRosa, J. C., DEEDWANIA, P. C., Shepherd, J., WENGER, N. K., Greten, H., DeMicco, D. A., & Breazna, A. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.025 · Cited by 66
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 64
Beyond Lipid Lowering: What Have We Learned About the Benefits of Statins from the Acute Coronary Syndromes Trials?
Ray, K. K., Cannon, C. P., & Ganz, P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.016 · Cited by 64
Self-citation
Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry
Leósdóttir, M., Schubert, J. R., Brandts, J., Gustafsson, S., Cars, T., Sundström, J., Jernberg, T., Ray, K. K., & Hagström, E. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.007 · Cited by 69
Self-citation
Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging
Lee, J., Wiesmann, F., Shirodaria, C. C., Leeson, P., Petersen, S. E., Francis, J. M., Jackson, C., Robson, M. D., Neubauer, S., Channon, K. M., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.001 · Cited by 62
Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness
Migrino, R. Q., Bowers, M. R., Harmann, L. M., Prost, R. W., & LaDisa, J. F. (2011) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-13-37 · Cited by 60
Atorvastatin reduces T ‐cell activation and exhaustion among HIV ‐infected c ART ‐treated suboptimal immune responders in U ganda: a randomised crossover placebo‐controlled trial
Nakanjako, D., Ssinabulya, I., Nabatanzi, R., Bayigga, L., Kiragga, A. N., Joloba, M. L., Kaleebu, P., Kambugu, A., Kamya, M. R., Sékaly, R., et al. (2014) · Tropical Medicine & International Health · doi:10.1111/tmi.12442 · Cited by 61
12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome
Yun, K. H., Oh, S. K., Rhee, S. J., Yoo, N. J., Kim, N., & Jeong, J. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.052 · Cited by 59
The Cholesterol Paradox in Heart Failure
Velavan, P., Loh, P. H., Clark, A. L., & Cleland, J. G. F. (2007) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2007.07211.x · Cited by 58
Role of Statins in Coronary Artery Disease
Lim, S. Y. (2013) · Chonnam Medical Journal · doi:10.4068/cmj.2013.49.1.1 · Cited by 60
Mechanism of action of anti-hypercholesterolemia drugs and their resistance
Tiwari, V., & Khokhar, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.048 · Cited by 60
Statin diabetogenicity: guidance for clinicians
Ray, K. K. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s3 · Cited by 55
Self-citation
Rationale, Design, and Implementation of Aggressive Risk Factor Management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial
Turan, T. N., Lynn, M., Nizam, A., Lane, B. F., Egan, B. M., Le, N., Lopes-Virella, M. F., Hermayer, K. L., Benavente, O., White, C. L., et al. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966911 · Cited by 54
Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina
Niccoli, G., Biasucci, L. M., Biscione, C., Fusco, B., Porto, I., Leone, A. M., Bona, R. D., Dato, I., Liuzzo, G., & Crea, F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.01.009 · Cited by 54
Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients
Roman, R. M., Camargo, P. V. S., Borges, F. K., Rossini, A. P. W., & Polanczyk, C. A. (2010) · Coronary Artery Disease · doi:10.1097/mca.0b013e328333f50d · Cited by 52
Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome
Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303932 · Cited by 53
Effects of statin therapy on progression of mild noncalcified coronary plaque assessed by serial coronary computed tomography angiography: A multicenter prospective study
Li, Z., Hou, Z., Yin, W., Liu, K., Gao, Y., Xu, H., Yu, F., Ma, Z., Yu, W., Yang, L., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.023 · Cited by 47
Smooth muscle glucose metabolism promotes monocyte recruitment and atherosclerosis in a mouse model of metabolic syndrome
Wall, V., Barnhart, S., Kanter, J. E., Kramer, F., Shimizu‐Albergine, M., Adhikari, N., Wight, T. N., Hall, J. L., & Bornfeldt, K. (2018) · JCI Insight · doi:10.1172/jci.insight.96544 · Cited by 46
Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events
Arca, M., & Gaspardone, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00004 · Cited by 47
Early Intervention With Rosuvastatin Decreases the Lipid Components of the Plaque in Acute Coronary Syndrome - Analysis Using Integrated Backscatter IVUS (ELAN Study) -
Otagiri, K., Tsutsui, H., Kumazaki, S., Miyashita, Y., Aizawa, K., Koshikawa, M., Kasai, H., Izawa, A., Tomita, T., Koyama, J., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-0600 · Cited by 43
Statins decrease mean platelet volume irrespective of cholesterol lowering effect
Sıvrı, N., Tekin, G., Yalta, K., Aksoy, Y., Şenen, K., & Yetkın, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0259 · Cited by 41
Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin
Kido, K., Wheeler, M. B., Seratnahaei, A., Bailey, A. L., & Bain, J. A. (2015) · Journal of the American Pharmacists Association · doi:10.1331/japha.2015.14151 · Cited by 38
Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis
Safouris, A., Krogias, C., Sharma, V. K., Katsanos, A. H., Faissner, S., Roussopoulou, A., Zompola, C., Kneiphof, J., Kargiotis, O., Deftereos, S. G., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309292 · Cited by 37
Interaction between Mediterranean diet and statins on mortality risk in patients with cardiovascular disease: Findings from the Moli-sani Study
Bonaccio, M., Castelnuovo, A. F. D., Costanzo, S., Persichillo, M., Curtis, A. D., Cerletti, C., Donati, M. B., de Gaetano, G., & Iacoviello, L. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.117 · Cited by 39
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy
Geisler, T., Zuern, C. S., Paterok, M., Göhring, K., Bigalke, B., Stellos, K., Seizer, P., Kraemer, B. F., Dippon, J., May, A. E., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn212 · Cited by 37
The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators—A pilot study
Kucera, M., Baláž, D., Kružliak, P., Ciccocioppo, R., Oravec, S., Rodrigo, L., Zulli, A., Hirnerova, E., Sabaka, P., Komorníková, A., et al. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.02.010 · Cited by 35
Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction
Aydın, M. Ü., Aygül, N., Altunkeser, B. B., Ünlü, A., & Taner, A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.003 · Cited by 37
Do structural differences in statins correlate with clinical efficacy?
Arnaboldi, L., & Corsini, A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833b776c · Cited by 35
Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: Versión resumida
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2008) · Revista Española de Cardiología · Cited by 33
Relation Between Soluble Intercellular Adhesion Molecule-1, Statin Therapy, and Long-Term Risk of Clinical Cardiovascular Events in Patients With Previous Acute Coronary Syndrome (from PROVE IT-TIMI 22)
Ray, K. K., Morrow, D. A., Shui, A. M., Rifai, N., & Cannon, C. P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.04.024 · Cited by 34
Self-citation
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study
Reckless, J. P. D., Henry, P., Pomykaj, T., Lim, S. T., Massaad, R., Vandormael, K., Johnson‐Levonas, A. O., Lis, K., Brudi, P., & Allen, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01697.x · Cited by 35

Authors: Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
Monash University (AU)
Harvard University (US)
Guy's Hospital (GB)
Corresponding author: Cannon, Christopher P.
ORCID: Ray, Kausik K.
Cannon, Christopher P.
Tonkin, Andrew M.
Sacks, Frank M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-10
Volume: 46
Issue: 8
Pages: 1405-1410
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2005.03.077
OpenAlex: W1484156179
Cited by: 356
References: 9
Citations by year: 2026: 10 · 2025: 13 · 2024: 5 · 2023: 12 · 2022: 13 · 2021: 4 · 2020: 15 · 2019: 11 · 2018: 17 · 2017: 15 · 2016: 14 · 2015: 11 · 2014: 18 · 2013: 20 · 2012: 24
FWCI: 26.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2845 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: atorvastatin, acute coronary syndrome, high-intensity statin therapy, pravastatin, PROVE IT-TIMI 22, pleiotropy, myocardial infarction, hospital readmission, long-term clinical outcomes
MeSH terms: Atorvastatin, Acute Disease, Angina, Unstable, Double-Blind Method, Female, Heptanoic Acids, Humans, Male, Middle Aged, Myocardial Infarction, Pyrroles, Syndrome, Time Factors, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks